Critical Survey: Sientra (SIEN) and The Competition
Sientra (NASDAQ: SIEN) is one of 84 publicly-traded companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it contrast to its rivals? We will compare Sientra to related companies based on the strength of its earnings, profitability, dividends, analyst recommendations, institutional ownership, risk and valuation.
Volatility & Risk
Sientra has a beta of -1.43, indicating that its stock price is 243% less volatile than the S&P 500. Comparatively, Sientra’s rivals have a beta of 1.06, indicating that their average stock price is 6% more volatile than the S&P 500.
Insider and Institutional Ownership
77.6% of Sientra shares are held by institutional investors. Comparatively, 66.2% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by institutional investors. 28.1% of Sientra shares are held by company insiders. Comparatively, 11.0% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This is a summary of current ratings and recommmendations for Sientra and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Sientra currently has a consensus price target of $13.75, indicating a potential downside of 5.50%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 7.09%. Given Sientra’s rivals higher possible upside, analysts clearly believe Sientra has less favorable growth aspects than its rivals.
This table compares Sientra and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares Sientra and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Sientra||$28.68 million||-$35.42 million||-5.47|
|Sientra Competitors||$827.23 million||$159.50 million||41.26|
Sientra’s rivals have higher revenue and earnings than Sientra. Sientra is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Sientra rivals beat Sientra on 8 of the 12 factors compared.
Sientra Company Profile
Sientra, Inc. is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons. Its breast implants are primarily used in elective procedures, which are generally performed on a cash-pay basis. TRUE Texture provides texturing on the implant shell that is designed to reduce the incidence of malposition, rotation and capsular contracture. The Company also offers breast tissue expanders and a range of other aesthetic and specialty products. The Company offers a range of HSC+ breast implants, including anatomically shaped textured, round textured and round smooth. The Company also offers miraDry system, the device to reduce underarm sweat, odor and permanently reduce hair of all colors.
Receive News & Ratings for Sientra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.